Talk:Oncolytic virus

Review of pediatric use
[http://www.nbglobe.com/2010/11/19/status-on-oncolytic-virus-therapies-for-pediatric-solid-tumors/ Status on oncolytic virus therapies for pediatric solid tumors - A review of a new therapy for neuroblastoma] summarises history, adult work and current pediatric trials. Can we use this source (it gives references) in the article even though it seems to be a blog ? Rod57 (talk) 20:58, 25 November 2010 (UTC)
 * Should be alright for uncontroversial information. They seemed to have sourced most of the info from this 2010 review. It would be better to cite that, although don't take the blogs word for it (drop me a line on my talk page if you can't access it). Also a quick NCBI search turned up this which is free and may also be useful. AIR corn (talk) 04:45, 26 November 2010 (UTC)

JX-954 and/or JX-594
JX-954 and/or JX-594? 99.190.82.45 (talk) 02:11, 5 September 2011 (UTC)
 * JX-594 is now mentioned under clinical research/Phase II. - Rod57 (talk) 02:46, 5 February 2016 (UTC)

Intro needs updating now T-VEC is approved
also where T-VEC is mentioned in the new section on Approved agents - detail is out of date - Rod57 (talk) 02:20, 5 February 2016 (UTC)

The automatic contents list is not showing subsections
Are subsections suppressed somewhere - it would be useful to show them. - Rod57 (talk) 02:45, 5 February 2016 (UTC)

Section "reporting" on clinical trials
The section below seems entirely built by people going into clinicaltrials.gov and "reporting" on what is there.

This is not what we do in WP. Somebody can do this on their blog perhaps... The "lead" sentence is ridiculous in talking about the period from 2014-2018 and having a ref from 2016 (actually accepted in Nov 2015)

The more specific section below the table, is also done in the spirit of trying to provide "news" with language about some trial "ongoing" or "has started", all with no dates. One big WP:RELTIME ball of confusion. A bunch of raw spam "sources" as well. None of this is appropriate to the mission, as it is  written.

In 2014-2018 period a number of clinical trials were initiated for a wide range of oncolytic virus products, reflecting the ongoing clinical development of this class of therapy.
 * Clinical research==

Abbreviations: 5-FC, 5-fluorocytosine; GM-CSF, granulocyte macrophage colony-stimulating factor; IFNγ, interferon γ; MAGEA3, melanoma antigen family A3; s.c., sub cutem.*initiated between 2014, March 1 and 2015, October 31.

Approved somewhere

 * Talimogene laherparepvec was approved by the US FDA in 2015, with the brand name Imlygic, for the treatment of melanoma in patients with inoperable tumors. In Jan 2016 it was approved in Europe for some inoperable melanoma.
 * Oncorine, by Shanghai Sunway Biotech, was approved in China for Head and neck cancer in 2005. It is based on the adenovirus H101.
 * RIGVIR, approved for melanoma treatment in Latvia (2004), then suspended 2019, Georgia (2015) and Armenia (2016) for melanoma treatment.

RIGVIR section needs updates
Article still lists Rigvir as approved somewhere, but its licence has been suspended in 2019 and in Latvian media there is talk of a criminal offence having been commited. Please see original ECHO-7 article for latest news: KC LV (talk) 08:18, 12 July 2019 (UTC)

Started phase III

 * JX-594, by SillaJen, is currently in phase III for Hepatocellular Carcinoma. Pexastimogene Devacirepvec(Pexa Vec) is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells. JX-594 is a thymidine kinase-deleted Vaccinia virus plus GM-CSF.
 * Reolysin, by Oncolytics Biotech, is in phase III for head and neck cancer. An interim data release showed that this phase III had already obtained statistically significant tumor shrinkage in patients at their 6-week scan, although the trial will not be complete until the overall survival data matures. Encouraging early results in colorectal cancer. In total there are 31 clinical studies either completed or ongoing, including many testing Reolysin alongside standard chemotherapies in a variety of solid cancers.

Started phase II

 * JX-594, by SillaJen, is currently in phase II for Solid Tumors. JX-594 is a thymidine kinase-deleted Vaccinia virus plus GM-CSF.
 * GL-ONC1, a modified vaccinia virus by Genelux Corporation, is in a Phase II study of intraperitoneal administration in patients with recurrent ovarian cancer. It is also in a Phase Ib study, administered intravenously for solid tumours. Additional trials are ongoing utilizing alternative methods of administration including intrapleural administration for patients with malignant pleural effusion, intraperitoneal injection for patients with advanced peritoneal carcinomatosis, and intravenous injection in combination therapy in head and neck cancers.
 * Seneca Valley virus (NTX-010) and (SVV-001), oncolytic picornavirus, is in phase II for small cell lung cancer and neuroblastoma.
 * ColoAd1 was developed by Psioxus Therapeutics Ltd using the process of directed evolution. ColoAd1 has successfully completed recruitment in a Phase I clinical trials of ColoAd1. The trial involved recruiting patients with metastatic solid tumours where no standard treatment options were applicable. Samples from these patients showed evidence of virus replication within tumour sites after intravenous delivery. The second phase of the ColoAd1 study is planned to commence in 2014 and will examine efficacy in patients with metastatic colorectal cancer. Unlike many other oncolytic viruses, ColoAd1 can be administered by intravenous injection rather than requiring intra-tumoral injection. A second trial is comparing the efficacy of the intravenous approach versus direct intra-tumoural injection to assess the most effective method of delivering ColoAd1 to cancer patients (see the EU Clinical Trials Register for further details). A third trial is examining the intra-peritoneal route of delivery for women with late stage ovarian cancer.
 * Cavatak is a coxsackie virus which is in phase II clinical trials for the treatment of malignant melanoma.
 * ONCOS-102 is an engineered human serotype 5/3 adenovirus coding for human GM-CSF optimized to induce systemic anti-tumor T cell response in cancer patients. It has started a phase II trial for Unresectable Malignant Pleural Mesothelioma. It has completed a phase I trial and is starting another for malignant pleural mesothelioma (MPM).

Started phase I

 * SEPREHVIR (HSV-1716), by Virttu Biologics completed phase I in glioblastoma, in squamous cell carcinoma of head and neck, and in melanoma. Ongoing phase I dose escalation study of intratumoral HSV-1716 in pediatric/young adult patients with non–central nervous system solid tumours and a new phase I/IIa study in mesothelioma commenced in 2012.
 * CGTG-102 (Ad5/3-D24-GMCSF), by Oncos Therapeutics, while in phase I was already used to treat 200 advanced cancer patients in the company's Advanced Therapy Access Program.
 * MV-NIS, an engineered measles virus has shown to be effective in targeted destruction of myeloma plasma cells. Radioactive Iodine imaging provides a novel technique for NIS gene expression monitoring.
 * DNX-2401 is an oncolytic adenovirus with US Orphan drug status for glioma.

-- Jytdog (talk) 20:41, 15 June 2018 (UTC)

Rigvir
Is the assessment here unbiased? The negative material appears based on a blog and news sources but a 2018 review in the European Journal of Pharmacology appears cautiously positive. Espresso Addict (talk) 03:46, 16 April 2019 (UTC)